Commitment during stenotele differentiation in Hydra is localized near the S/G2 boundary in the terminal cell cycle [PDF]
, 1982 The timing of commitment during stenotele differentiation in Hydra was determined. Regeneration of isolated distal regions of the body column induces stenotele differentiation.
Berking +16 more
core +1 more source
Frontiers in Genetics, 2020 Background: Sickle cell disease, the inherited blood disorder characterized by anemia, severe pain and other vaso-occlusive complications, acute chest syndrome, disproportionate hospitalization, and early mortality, has significant financial, social, and
O. Chide +12 more
semanticscholar +1 more source
Drugs for preventing red blood cell dehydration in people with sickle cell disease. [PDF]
, 2016 BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications.
Ballas, Samir K., Nagalla, Srikanth
core +2 more sources
Blood Advances, 2020 Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low among individuals with SCD. The objective of this study was to examine barriers to patients' adherence to hydroxyurea use regimens by using the intentional and ...
Jason R. Hodges +13 more
semanticscholar +1 more source
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]
, 2018 We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo +41 more
core +5 more sources
Comorbidities in aging patients with sickle cell disease. [PDF]
, 2018 Sickle cell disease (SCD) in general and sickle cell anemia in particular is a highly complex disorder both at the molecular and clinical levels. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing ...
Ballas, Samir K.
core +2 more sources
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease [PDF]
, 2017 Key Points Regadenoson did not reduce iNKT cell activation to a prespecified level when administered to patients with SCD. Because iNKT cell activation was not reduced, the benefit of iNKT cell-based therapies in SCD cannot be determined.
Achebe, Maureen +14 more
core +2 more sources
Cells, 2021 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a dismal prognosis. Here, we show how an inhibition of de novo dNTP synthesis by the ribonucleotide reductase (RNR) inhibitor hydroxyurea and an inhibition of epigenetic ...
Alexandra Nguyen +5 more
doaj +1 more source
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]
, 2020 Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core +1 more source
Patients with Essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis [PDF]
, 2002 A significant proportion of patients with Essential Thrombocythaemia (ET) have thrombotic complications which have an important impact upon the quality, and duration of their life.
Carr, P. +5 more
core +1 more source